Related Experiment Video
Updated: Aug 7, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Identification of a constitutively active mutant of JAK3 by retroviral expression screening
Young Lim Choi1, Ruri Kaneda, Tomoaki Wada
1Division of Functional Genomics, Jichi Medical University, 3311-1 Yakushiji, Shimotsukeshi, Tochigi 329-0498, Japan.
Abstract:
To identify transforming genes in acute myeloid leukemia (AML) we here constructed a retroviral cDNA expression library from an AML patient, and then used this library to infect a mouse cell line 32Dcl3-mCAT. cDNA inserts of the cell clones which proliferated in the presence of granulocyte colony-stimulating factor were derived from JAK3 encoding a JAK3 mutant with a valine-to-alanine substitution at codon 674 and two additional amino acid substitutions. The transforming activity of JAK3(V674A) was confirmed by its introduction into 32Dcl3-mCAT. Sequencing of the original JAK3 cDNA derived from the patient, however, failed to detect the V674A mutation.
Insights
Researchers identified a novel Janus Kinase 3 (JAK3) mutant driving acute myeloid leukemia (AML) proliferation. This JAK3(V674A) mutation was confirmed to transform cells, though it was not found in the original patient
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- Identifying novel transforming genes is crucial for understanding AML pathogenesis and developing targeted therapies.
Purpose of the Study:
- To identify novel transforming genes in acute myeloid leukemia (AML).
- To characterize the functional role of identified gene mutations in cellular transformation.
Main Methods:
- Construction of a retroviral cDNA expression library from AML patient samples.
- Infection of mouse cell line 32Dcl3-mCAT with the library.
- Identification and sequencing of cDNA inserts from proliferating cell clones.
- Functional validation of identified mutations through re-introduction into the cell line.
Main Results:
- A JAK3 mutant, JAK3(V674A), with two additional amino acid substitutions was identified.
- This JAK3 mutant demonstrated transforming activity in the 32Dcl3-mCAT cell line.
- The specific V674A mutation was not detected in the original patient's JAK3 cDNA.
Conclusions:
- A novel transforming JAK3 mutant was identified in the context of AML.
- The JAK3(V674A) mutation possesses oncogenic potential, driving cellular proliferation.
- The discrepancy in mutation detection suggests potential complexities in AML genetics or experimental artifacts.
